Vitamin D deficiency in adulthood: Presentation of 2 familial cases simulating pseudohypoparathyroidism

Manero-Azua, África; Pereda, Arrate; González Cabrera, Natalia; Martínez de Salinas Santamaría, M. Ángeles; Cámara Balda, Alejandro; Pérez de Nanclares, Guiomar

doi:10.1016/j.medcle.2023.06.031

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of point variants in GNAS was investigated using Sanger sequencing as previously described [4]. Next-Generation Sequencing was performed with a custom panel as previously described [41].…”

Section: Molecular Analysesmentioning

confidence: 99%

Choosing the Best Tissue and Technique to Detect Mosaicism in Fibrous Dysplasia/McCune–Albright Syndrome (FD/MAS)

Vado,

Manero-Azua,

Pereda

et al. 2024

Genes

View full text Add to dashboard Cite

GNAS-activating somatic mutations give rise to Fibrous Dysplasia/McCune–Albright syndrome (FD/MAS). The low specificity of extra-skeletal signs of MAS and the mosaic status of the mutations generate some difficulties for a proper diagnosis. We studied the clinical and molecular statuses of 40 patients referred with a clinical suspicion of FD/MAS to provide some clues. GNAS was sequenced using both Sanger and Next-Generation Sequencing (NGS). We were able to identify the pathogenic variants in 25% of the patients. Most of them were identified in the affected tissue, but not in blood. Additionally, NGS demonstrated the ability to detect more patients with mosaicism (8/34) than Sanger sequencing (4/39). Even if in some cases, the clinical information was not complete, we confirmed that, as in previous works, when the patients were young children with a single manifestation, such as hyperpigmented skin macules or precocious puberty, the molecular diagnosis was usually negative. In conclusion, as FD/MAS is caused by mosaic variants, it is essential to use sensitive techniques that allow for the detection of low percentages and to choose the right tissue to study. When not possible, and due to the low positive genetic rate, patients with FD/MAS should only be genetically tested when the clinical diagnosis is really uncertain.

show abstract

Section: Molecular Analysesmentioning

confidence: 99%